NEW YORK (GenomeWeb News) – Abbott yesterday said that it will partner with Pfizer on a molecular diagnostic test to screen non-small cell lung cancer tumors for the presence of gene rearrangements.

Pfizer is developing a drug that selectively targets cancer-causing genes implicated in the progress of many cancers, the firms said in a statement. For patients to be eligible to receive the drug candidate, a particular genetic translocation known to be present in NSCLC tumors and others cancers, but not in normal cells, must be identified in the tumor sample.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The US National Institutes of Health has developed guidelines to gauge whether frail chimpanzees are healthy enough to be moved to a retirement sanctuary.

Osamu Shimomura, who won the 2008 Nobel Prize in Chemistry for his work on green fluorescent protein, has died.

In PLOS this week: analytical approach for finding new genetic associations, analysis of Streptococcus pyogenes-infecting viruses, and more.

Stat News reports that the head of IBM Watson Health is leaving her post.

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Sponsored by

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.